Polycystic kidney disease interventions

	Polycystic kidney disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Polycystic kidney disease from other Diseases
Epidemiology and Demographics
Risk Factor
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Polycystic kidney disease interventions On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Polycystic kidney disease interventions All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Polycystic kidney disease interventions
CDC on Polycystic kidney disease interventions
Polycystic kidney disease interventions in the news
Blogs on Polycystic kidney disease interventions
Directions to Hospitals Treating Polycystic kidney disease
Risk calculators and risk factors for Polycystic kidney disease interventions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]

Overview

Dialysis is not the first-line treatment option for patients with polycystic kidney disease. Dialysis is usually reserved for patients with either end stage renal disease (ESRD) or renal failure.

Indications

Dialysis is not the first-line treatment option for patients with polycystic kidney disease. Dialysis is usually reserved for patients with either:^[1]

Dialysis

Dialysis is the mainstay of treatment for ESRD and renal failure in patients with polycystic kidney disease^[2]
Peritoneal dialysis may have a survival benefit over hemodialysis^[3]
Hemodialysis is the preferred modality for renal replacement in patients with polycystic kidney disease^[2]

Contraindications

Peritoneal dialysis is not preferred in patients with PKD, because of the lack of ability to acoomodate large volume of peritoneal fluid^[4]
Peritoneal dialysis is also avoided in patients with aortic aneurysms
Anticoagulants required for hemodialysis should be used with caution due to pre existing hematuria

References

↑ Grantham JJ (October 2008). "Clinical practice. Autosomal dominant polycystic kidney disease". N. Engl. J. Med. 359 (14): 1477–85. doi:10.1056/NEJMcp0804458. PMID 18832246.
↑ ^2.0 ^2.1 Pirson Y, Christophe JL, Goffin E (1996). "Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease". Nephrol. Dial. Transplant. 11 Suppl 6: 24–8. PMID 9044324.
↑ Abbott KC, Agodoa LY (March 2002). "Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival". Clin. Nephrol. 57 (3): 208–14. PMID 11924752.
↑ Lederman ED, McCoy G, Conti DJ, Lee EC (February 2000). "Diverticulitis and polycystic kidney disease". Am Surg. 66 (2): 200–3. PMID 10695753.

Template:WH Template:WS

[pmid18832246-1] Grantham JJ (October 2008). "Clinical practice. Autosomal dominant polycystic kidney disease". N. Engl. J. Med. 359 (14): 1477–85. doi:10.1056/NEJMcp0804458. PMID 18832246.

[pmid9044324-2] 2.0 ^2.1 Pirson Y, Christophe JL, Goffin E (1996). "Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease". Nephrol. Dial. Transplant. 11 Suppl 6: 24–8. PMID 9044324.

[pmid11924752-3] Abbott KC, Agodoa LY (March 2002). "Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival". Clin. Nephrol. 57 (3): 208–14. PMID 11924752.

[pmid10695753-4] Lederman ED, McCoy G, Conti DJ, Lee EC (February 2000). "Diverticulitis and polycystic kidney disease". Am Surg. 66 (2): 200–3. PMID 10695753.

[1]

[2]

[3]

[4]